Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

728
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728
Tumor Progression02:07

Tumor Progression

7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.7K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant Chemotherapy with Trastuzumab with or without Concurrent Radiotherapy in HER2-Positive Locally Advanced Inoperable Breast Cancer- A Phase 2 Randomized Controlled Trial (NEOTRAC STUDY).

International journal of radiation oncology, biology, physics·2026
Same author

Identifying the Presence and Characteristics of Mid-Myocardial and Epicardial Fibrosis From Intracardiac Electrograms in Patients Undergoing Ventricular Arrhythmia Ablation Using a Transformer-Based Self-Supervised Classifier.

Circulation. Arrhythmia and electrophysiology·2026
Same author

<b>Autologous Stem Cell Transplantation Of HIV-Positive Plasmablastic Lymphoma - Case Series</b>.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Antithetic Sampling Enhanced Probabilistic Diffusion for Denoising Cardiac Time Series.

IEEE journal of biomedical and health informatics·2026
Same author

Targeted metabolomic profiling of gastric cancer biopsies.

The Indian journal of medical research·2026
Same author

Radiation-induced Osteosarcoma of the vaginal vault following cervical cancer treatment.

BMJ case reports·2026

Related Experiment Video

Updated: Dec 21, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.1K

"Hairy Cell Leukemia (HCL): 'Real World' Outcome".

Archit Joshi1, Manikandan Dhanushkodi1, Prasanth Ganesan1

  • 11Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu 600036 India.

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
|May 20, 2020
PubMed
Summary
This summary is machine-generated.

Hairy cell leukemia (HCL) is a rare B-cell cancer. Indian patients treated with cladribine or interferon showed high complete response rates and survival comparable to Western cohorts.

Keywords:
Hairy cell leukemiaOutcomeSurvival

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

460
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.3K

Related Experiment Videos

Last Updated: Dec 21, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.1K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

460
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

10.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Hairy cell leukemia (HCL) is an uncommon B-cell lymphoproliferative disorder.
  • Limited data exists on the long-term outcomes of HCL in India.

Purpose of the Study:

  • To evaluate the long-term outcomes of HCL patients treated in India.
  • To assess treatment response, survival rates, and relapse patterns.

Main Methods:

  • Retrospective data collection from HCL patient records (2001-2018).
  • Analysis of treatment modalities including cladribine, interferon, and best supportive care.
  • Evaluation of complete response, disease-free survival (DFS), and overall survival (OS).

Main Results:

  • Sixteen HCL patients were analyzed, with 81% treated with cladribine.
  • All treated patients achieved complete response.
  • Five-year DFS was 77% and 5-year OS was 80%, with a 27% relapse rate.
  • Febrile neutropenia occurred in over half of patients, but no treatment-related mortality was observed.

Conclusions:

  • HCL is a curable malignancy with high remission rates.
  • Indian HCL patient outcomes are comparable to those reported in Western countries.
  • Cladribine and interferon are effective treatments for HCL, yielding favorable long-term survival.